It has been informed that miR-27b, miR-340, and miR-128 were increased in CD4+ T cells from MS patients and inhibit IL-4 expression, shift Th2 to Th1, suppress Th2 development, and leading to MS pathogenesis. Here, CD4 is linked to myeloid sarcoma.